Meeting
2021 ASCO Annual Meeting
Phase II study of brigatinib in ROS1 positive non-small cell lung cancer (NSCLC) patients previously treated with crizotinib: Barossa cohort 2.
Authors
Haruko Daga
Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan
Haruko Daga , Seiji Niho , Jun Sakakibara-Konishi , Hiroshi Tanaka , Yasushi Goto , Kadoaki Ohashi , Ryo Toyozawa , Masahiro Kodani , Toshiaki Takahashi , Yoshihiro Hattori , Masahiro Morise , Takaya Ikeda , Shingo Matsumoto , Kiyotaka Yoh , Shogo Nomura , Koichi Goto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
JapicCTI-194851
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9040)
DOI
10.1200/JCO.2021.39.15_suppl.9040
Abstract #
9040
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
TRUST-II: A global phase II study for taletrectinib in ROS1 fusion–positive lung cancer and other solid tumors.
First Author: Misako Nagasaka
Poster
2022 ASCO Annual Meeting
Brigatinib in Japanese patients (pts) with ALK+ NSCLC: Final results from the phase 2 J-ALTA trial.
First Author: Pingkuan Zhang
Poster
2021 ASCO Annual Meeting
Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.
First Author: Scott N. Gettinger
Poster
2020 ASCO Virtual Scientific Program
TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements.
First Author: Robert Charles Doebele